Adenosine operating in the nucleus of the solitary tract (NTS) may inhibit or facilitate neurotransmitter release from nerve terminals and directly inhibit or facilitate central neurons via A 1 and A 2a pre-and postsynaptic receptors, respectively. However, adenosine A 2a receptors, may also activate GABA-ergic neurons/terminals which in turn inhibit glutamatergic transmission in the NTS network. Our previous studies showed that adenosine operating via both A 1 (inhibitor) and A 2a (activator) receptors powerfully inhibits the cardiopulmonary chemoreflex (CCR) at the level of the caudal NTS. A 1 receptors most likely inhibit glutamate release in the CCR network, whereas A 2a receptors facilitate NTS GABA-ergic mechanisms which in turn inhibit CCR glutamatergic transmission. Therefore, we hypothesized that A 2a receptors are located on NTS GABA-ergic neurons/terminals whereas A 1 receptors may be located on NTS glutamatergic neurons/terminals. We investigated this hypothesis using double immunofluorescent staining for A 2a or A 1 adenosine receptors and GABA synthesizing enzyme, GAD67, in 30 lm thick, floating, medullary rat sections. We found that A 2a adenosine receptors are localized within the GABA-ergic cells in the caudal NTS, whereas A 1 adenosine receptors are absent from these neurons. Instead, A 1 receptors were located on non-GABAergic (likely glutamatergic) neurons/terminals in the caudal NTS. These data support our functional findings and the hypothesis that adenosine A 2a, but not A 1 receptors are located on GABA-ergic neurons.
Introduction
Adenosine is a powerful modulator of cardiovascular reflexes including the arterial baroreflex and cardiopulmonary chemoreflex (CCR) which are primarily integrated in the nucleus of the solitary tract (NTS) (Mosqueda-Garcia et al. 1989; Abdel-Rahman and Tao 1996; Spyer and Thomas 2000; Scislo et al. 2001 Scislo et al. , 2008 Scislo and O'Leary 2005; Ichinose et al. 2009 Ichinose et al. , 2012 Minic et al. 2014b) . Adenosine is released into the NTS during life-threatening situations such as ischemia, hypoxia, and severe hemorrhage (Winn et al. 1979; Van Wylen et al. 1986; Phillis et al. 1987; Yan et al. 1995; Scislo and O'Leary 2006; Minic et al. 2014a ). During severe hemodynamic imbalance, intracellular adenosine accumulates as a result of adenosine triphosphate (ATP) catabolism within hypoxic neurons and glial cells. The important role of adenosine in modulating cardiovascular control at the level of the NTS is supported by the fact that the NTS contains the highest amount of adenosine uptake sites within the entire central nervous system (Bisserbe et al. 1985) . The accumulated adenosine is released into the extracellular space and envelopes all neurons in the area (Winn et al. 1979; Van Wylen et al. 1986; Phillis et al. 1987; Yan et al. 1995; Scislo and O'Leary 2006; Minic et al. 2014a) . Despite this global release, adenosine evokes specific and contrasting effects on regional sympathetic outputs and blood pressure control by acting on two antagonistic A 1 and A 2a receptor subtypes which inhibit and facilitate neurotransmitter release, respectively, (Ralevic and Burnstock 1998; Scislo and O'Leary 2005) . In the NTS, the facilitator A 2a adenosine receptors functionally prevail over inhibitor A 1 adenosine receptors and this is evident by the observation that cardiovascular responses to exogenous adenosine (decreases in MAP and HR) are mimicked by agonists to A 2a receptors and not A 1 receptor agonists which evoke pressor responses and sympathoactivation (Mosqueda-Garcia et al. 1989; Abdel-Rahman and Tao 1996) . The specific actions of these two receptor subtypes is further highlighted by the observation that activation of A 1 adenosine receptors within the NTS inhibits baroreflex control of hemodynamic and sympathetic responses while activation of A 2a adenosine receptors at the level of the NTS does not alter processing within the baroreflex arc (Scislo et al. 2008; Ichinose et al. 2009 ). The fact that global release of adenosine as well as microinjection of selective adenosine receptor agonists evokes such specific responses, supports the hypothesis that adenosine receptor subtypes may be preferentially located on specific neural networks within the NTS (Scislo et al. 2001 (Scislo et al. , 2008 Scislo and O'Leary 2005; Ichinose et al. 2009 ).
The cardiopulmonary chemoreflex (CCR), also known as the von Bezold-Jarisch reflex is triggered by the activation of mostly polymodal mechano-and chemosensitive C afferent fibers which transmit information from the cardiopulmonary area in the chest via vagus nerve to the NTS (Coleridge et al. 1973; Paintal 1973 Paintal , 1977 Thor en 1977; Thor en et al. 1979a,b; Scislo et al. 1993 ). This reflex may be activated with serotonin (operating via 5HT 3 receptors) which is released during cardiac ischemia from aggregating platelets forming coronary thromboses, or from ischemic endothelial cells (Oei et al. 1983; Burnstock et al. 1988; Evans et al. 1990 ). Other neuroactive substances, naturally released during cardiac ischemia, may also activate cardiac vagal afferents, for example: endogenous cannabinoids operating via TRPV1 receptors, ATP operating via P2x receptors, nicotine etc. (Evans et al. 1991; Wagner et al. 2001; Rocha et al. 2003; Lupinski et al. 2011) . The CCR reactivity is enhanced during acute myocardial ischemia (Rocha et al. 2003; Lupinski et al. 2011) .
The CCR response: vasodilation, bradycardia, and decreases in renal, adrenal and lumbar sympathetic nerve activities may be beneficial by decreasing afterload on the heart. However, profound activation of the reflex may also lead to severe hypotension and cerebral ischemia; this may lead to fainting and even to sudden cardiac death of young athletes (Mark 1983; Greenberg 1984; Ng and Maginot 2007) . In the latter scenario, adenosine released into the NTS may act as a negative feedback regulator to fine tune this reflex and prevent the deadly over-activation of the CCR.
In support of this model, our previous studies showed that adenosine operating via both A 1 (inhibitor) and A 2a (activator) receptors powerfully inhibits the CCR at the level of the NTS. A 1 receptors most likely inhibit glutamate release in the CCR network (Ichinose et al. 2012) . Our recent studies indicated that adenosine A 2a receptors inhibit CCR transmission in the NTS (Minic et al. 2014b) and this inhibition occurs via a GABA-ergic mechanism (Minic et al. 2015) . A 2a adenosine mediated inhibition is markedly attenuated, that is, the CCR responses are restored following GABA-ergic blockade in the NTS. This suggests that A 2a receptors may be located on the NTS GABA-ergic neurons or terminals where they act to facilitate GABA release. Therefore, the present study tested the following hypotheses: (1) A 2a but not A 1 receptors colocalize with NTS GABA-ergic neurons/terminals; (2) A 1 receptors are located on NTS non-GABA-ergic (most likely glutamatergic) neurons in the caudal NTS where the CCR is integrated. To test these anatomical hypotheses, we utilized the technique of immunohistochemistry to investigate the localization of adenosine A 1 and A 2a receptors with respect to the NTS GABA-ergic neurons/ terminals expressing GAD67.
Methods
All animal experiments were approved by the Institutional Animal Care and Use Committee of Wayne State University and were performed in accordance with the Guide for the Care and Use of Laboratory Animals from the Institute of Laboratory Animals Resources and National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) .
Perfusion and tissue harvesting
Spraque-Dawley rats (n = 3, Charles Rivers, Wilmington, MA) were anesthetized with intraperitoneal injection of urethane (Sigma, St. Louis, MO) and transcardially perfused using oxygenated Dulbecco's Modified Eagle's Medium/Ham F12 Medium (Sigma), followed by fixation in 4% formaldehyde (Fisher Scientific, Waltham, MA). The medulla oblongata was excised and postfixed for 24 h (4% formaldehyde). The tissue was then placed into 20% sucrose solution for 2 days or until the tissue sank to the bottom of the vial and was sectioned at 30 lm using a cryostat (Leica Microsystems, Buffalo Grove, IL). transverse sections were transferred to 0.1 mol/L phosphate-buffered solution (Fisher) for immunohistochemical staining.
Immunohistochemistry
All incubations and washes were performed at room temperature and on a shaker. The tissue sections were exposed to 10% normal horse serum diluted in immunobuffer (0.03% Triton in 0.1 mol/L phosphate buffer) to block unspecific antibody binding. Sections were then incubated in primary antibodies: a) mouse anti-glutamic acid decarboxylase 67 (GAD67, 1:500, Millipore, Temecula, CA), b) rabbit anti-A 1 adenosine receptor (1:1000, Novus Biologicals, Littleton, CO), c) rabbit anti-A 2a adenosine receptor protein (1:1000, GenWay Bio, San Diego, CA) for 24 h. The monoclonal GAD67 antibody was raised against the cytoplasmic form of the GAD enzyme. The experiments conducted by Millipore confirmed the selectivity toward GAD67 and no detectable cross-reactivity with the GAD65 isoform of the enzyme (http://www.emdmillipore.com/US/ en/product/Anti-GAD67-Antibody-clone-1G10.2,MM_NF-MAB5406). The polyclonal adenosine A 1 receptor antibody was raised against a 20-amino acid synthetic peptide corresponding to C terminus (https://www.novusbio.com/pro ducts/adenosine-a1-r-antibody-epr6179_nbp1-96749). The experiments conducted by Novus Biologicals showed detection of A 1 adenosine receptor positive Purkinje neurons in rat brain sections. The monoclonal A 2a adenosine receptor antibody was raised against a peptide derived between 321 and 370 amino acids of the C-terminus of adenosine receptor gene. The experiments conducted by the manufacturer in HepG2 cell lines showed a single band at approximately 46 kDa corresponding to the A 2a adenosine receptor protein (https://www.genwaybio.com/huma n-adora2a-antibody-85299). Sections were washed three times in tris-PBS buffer and incubated overnight in secondary antibody: donkey anti-mouse immunoglobulin conjugated to Alexa488 (1:200, Jackson) to visualize GAD67 reactivity. To visualize A 1 or A 2a adenosine receptors, biotin-conjugated donkey anti-rabbit (1:500, Jackson) secondary antibody was incubated overnight followed by a 4-hour incubation with Cy3-conjugated streptavidin (1:1000 Jackson). Sections were mounted wet onto the microscope slides (Southern Biotech, Birmingham, AL) and the edges were sealed with clear nail polish.
Image acquisition
Tissue sections were examined using a Zeiss Axioplan2 (Thornwood, NY) conventional microscope. The band widths for Alexa488 (green) and Cy3 (red) filters used on the microscope to visualize immunoreactivity were selected such to avoid bleed-through. The excitation and emission spectrum for the green filter was set to: 490 and 525 AE 12 nm, respectively, while the excitation and emission spectrum for the red filter was set to: 595 and 620 AE 12 nm, respectively. Immunoreactive neurons were photographed using high-resolution Zeiss AxioCam MRm digital camera controlled by Zeiss, Axiovision software v4.8. Image J software was used to adjust the brightness, sharpness, and contrast.
Results
The present study demonstrates distinct localization of adenosine A 2a and A 1 receptor subtypes within the caudal NTS, where the CCR is integrated. A 2a adenosine receptors were expressed within GABA-ergic neurons/terminals (Fig. 1) , whereas A 1 adenosine receptors were localized on non-GABA-ergic neurons some of which may receive GABA-ergic input (Fig. 2) . GABA synthesizing neurons were identified by visualizing GAD67 immunofluorescence within the cell bodies or axon terminals in the caudal NTS. The top panel of Figure 1 is a schematic diagram of a brain section containing caudal NTS. The area of interest is delineated with the box. The bottom panels show a part of the box containing an NTS neuron expressing GAD67 (green, left) and A 2a adenosine receptors (red, middle) within the same field of view. The right panel shows overlay of the two channels and colocalization (yellow) of the GAD67 and A 2a adenosine receptors. We found positive A 2a adenosine receptor signal in 55 cells all of which also expressed GAD67. Figure 2 represents a photomicrograph from a region of the caudal NTS delineated in the schematic and enlarged below. The bottom panels show GAD67-positive axons/terminals (left panel), and A 1 adenosine receptor positive cell bodies (middle panel) all within the same field of view. The right panel shows an overlay of the two channels. We found 64 A 1 adenosine receptor positive cells, of which none expressed GAD67 suggesting that A 1 adenosine receptors are not present on GABA-ergic axons/terminals in the caudal region of the NTS. However, in some instances (as in Fig. 2 ), GABA containing axons were found in close proximity to A 1 adenosine receptor positive cells.
Discussion
The present study for the first time provided direct anatomical evidence for specific localization of A 1 and A 2a adenosine receptors in the CCR network at the level of the caudal NTS. These data support our functional studies which suggest differential expression of A 1 versus A 2a adenosine receptors on the NTS neurons involved in the processing of the CCR (Ichinose et al. 2012; Minic et al. 2015) . The major finding of the study is colocalization of A 2a , but not A 1 adenosine receptors with GABA synthesizing neurons in the NTS. A 1 adenosine receptors were expressed within NTS non-GABA-ergic neurons which receive GABA-ergic projections. These observations were restricted to the caudal regions of the NTS involved in processing of the CCR information. These data further support the hypothesis based on our previous functional studies that adenosine A 1 receptors inhibit CCR via direct inhibition of NTS neurons/interneurons mediating this reflex (Ichinose et al. 2012 ). In contrast, adenosine A 2a receptors inhibit CCR network via facilitation of neurotransmitter release from GABA-ergic neurons in the NTS (Minic et al. 2015) . Adenosine receptor mediated GABA release at the level of the NTS and other CNS structures has been observed previously (Hettinger et al. 2001; Zaidi et al. 2006; Duy et al. 2010 ). Duy showed modulation of laryngeal chemoreflex by adenosinergic and GABA-ergic mechanisms (Duy et al. 2010) . Hettinger et al. (2001) demonstrated A 2a adenosine receptor modulation of GABA-ergic signaling in striatum while Zaidi et al. (2006) reported A 2a adenosine receptor mRNA expression within GABAergic neurons involved in respiration. A 1 adenosine receptors, on the other hand, were found on NTS neurons surrounded by GABA-ergic axons/terminals. Functional studies have demonstrated A 1 adenosine receptor mediated inhibition of neurotransmitter release and inhibition of glutamatergic signaling, suggesting that NTS neurons on which A 1 adenosine receptors were visualized in the present study may be of glutamatergic phenotype (Dunwiddie and Fredholm 1989; Banie and Nicholls 1993; De Mendonc ßa et al. 1995; Scislo et al. 2008; Ichinose et al. 2012) . These studies support our previous functional findings as well as the findings of the current study that both A 1 and A 2a adenosine receptors are present in the caudal NTS and play an important role in differential modulating neurotransmitter release within the cardiovascular reflexes integrated there (Scislo et al. 2008; Ichinose et al. 2009 Ichinose et al. , 2012 Minic et al. 2014b Minic et al. , 2015 .
In summary, the present neuroanatomical data as we predicted are based on previous functional studies and are summarized diagrammatically in Figure 3 . A 1 receptors are located on non-GABA-ergic (likely glutamatergic) neurons and directly inhibit the CCR network via inhibition on neurotransmitter release, whereas A 2a receptors indirectly inhibit neurotransmitssion in the CCR pathway via facilitating neurotransmitter release from GABA-ergic neurons which then inhibit further neuronal activity in the CCR network.
Our data suggest, but do not prove, that A 1 adenosine receptors inhibit the CCR via direct inhibitory action on NTS glutamatergic neurons mediating the CCR. Whether A 1 adenosine receptors colocalize with NTS glutamatergic neurons which mediate the CCR should be addressed in future studies. The major limitation of this study is that the projection targets of GABA-ergic and non-GABAergic neurons are not identified. GABA-ergic neurons are most likely intrinsic NTS neurons involved in negative feedback present in the CCR and other cardiovascular reflexes integrated in the NTS (Zhang and Mifflin 2010) . However, further studies should examine if NTS A 1 -receptor-expressing glutamatergic neurons may be labeled retrogradely from the caudal ventrolateral medulla, which mediates CCR. Since both A 1 and A 2a receptors are present on vagal afferents terminating in the NTS (CastilloMelendez et al. 1994; Krstew et al. 1998 ) there is also possibility that A 1 (inhibitor) but not A 2a (activator) receptors are located on vagal afferents mediating the CCR. If so, adenosine operating via A 1 receptors could exert direct inhibition of glutamate release from CCR afferents as well as from NTS glutamatergic neurons (Castillo-Melendez et al. 1994; Krstew et al. 1998; Ichinose et al. 2012 ). This possibility should be also addressed in future studies.
Conclusion and Perspectives
The present neuroanatomical data support our previous functional findings suggesting that adenosine operating in the NTS via both A 1 and A 2a receptors exerts powerful inhibition of the CCR. A 1 receptors directly inhibit glutamatergic transmission in the CCR network whereas A 2a receptors exert indirect inhibition via facilitation of the release of GABA which in turn inhibits the CCR. The pronounced CCR-induced bradycardia and depressor responses may lead to brainstem ischemia and release of adenosine as a product ATP breakdown within ischemic cells. Similarly, adenosine is released into the NTS during hypotensive stage of severe hemorrhage and alters hemodynamic and regional sympathetic responses to hemorrhage via both A 1 and A 2a adenosine receptors (Minic et al. 2014a) . In both situations, adenosine may prevent further dangerous decreases of arterial blood pressure and brainstem ischemia thereby aiding in the restoration of circulatory homeostasis.
